PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “ERYTHROPOIESIS”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 631 records · Page 35Linked to original sources

[In vitro studies for evaluating the influence of recombinant interleukin-11 on human erythropoiesis. Potential clinical implications].

According to the experimental data that IL-11 costimulates the proliferation of human hematopoietic progenitors in vitro the first clinical trials in vivo have been performed. Surprisingly, the patients treated with recombinant Il-11 display decrease in the hematocrit values. This finding is contradictory to previous experimental studies in vitro, where IL-11 was found to be a potent costimulator of eytrhopoiesis. Therefore in order to obtain our own data the influence of IL-11 on human erythropoiesis in vitro has been reevaluated. In performed studies we did not observed any influence of IL-11 on the cloning efficiency of human erythropoietic progenitors in vitro. Our results demonstrate on one side that clinical use of IL-11 in order to stimulate erythropoiesis is not enough theoretically grounded and on the other that the decrease of hematocrit values observed after in vivo treatment with recombinant IL-11 could not be explained simply by the fact of the possibility of the direct inhibition of erythroid colonies formation by Il-11.

Clone Cells↗

Dysregulated expression of GATA-1 following retrovirus-mediated gene transfer into murine hematopoietic stem cells increases erythropoiesis.

Retrovirus-mediated gene transfer was used to study the effects of dysregulated expression of the zinc-finger transcription factor, GATA-1, which has been shown to be required for erythropoiesis. A retroviral vector (PGK-GATA-1) was constructed with the murine GATA-1 gene linked to the human phosphoglycerate kinase (PGK) promoter. Expression of GATA-1 was demonstrated by super-shift analysis with a monoclonal antibody against murine GATA-1 using extracts of nonerythroid cytotoxic T-lymphocyte line (CTLL) cells transduced with the PGK-GATA-1 virus. Mouse bone marrow cells were transduced in vitro and transplanted into recipient animals. Polymerase chain reaction (PCR) analysis performed on DNA extracted from peripheral blood 12 to 40 weeks posttransplantation demonstrated the presence of the PGK-GATA-1 provirus. Proviral integrity and copy number were demonstrated by Southern blot analysis of DNA from spleen, thymus, and bone marrow tissues from the long-term animals. At 16 weeks posttransplant, animals that received cells transduced by the GATA-1 virus maintained a lower white blood cell (WBC) count and absolute neutrophil count (ANC) and a higher red blood cell (RBC) count than control animals that received cells transduced with a virus containing a neor gene. Erythropoiesis was stimulated in GATA-1 and control animals by phlebotomy. GATA-1 animals required more extensive phlebotomy to reach a hematocrit less than 25 and their hematocrit returned to normal levels sooner than control animals. The effect of twice-daily injections of 10 U recombinant erythropoietin (epo) was also examined. The hematocrit of GATA-1 animals showed a more rapid and elevated response to epo than the hematocrit of control animals. These data suggest that dysregulated expression of GATA-1 in primitive hematopoietic cells enlarges the pool of epo-responsive erythroid progenitor cells.

Anemia↗

[Ineffective erythropoiesis in myeloid splenomegaly: the 59Fe test, bone marrow histologic and cytologic data].

Eight patients presenting primary myelofibrosis or spent polycythemia were submitted to a ferrokinetic study, a triphine bone marrow biopsy and a bone marrow puncture. In all cases before treatment (splenic radiotherapy) ferrokinetic measurements demonstrated an ineffective erythropoiesis, the intensity of which was precised on bone marrow biopsies, in numbering the erythroblasts per surface unit. Bone marrow biopsies permitted also, through a semiquantitative estimate of the bone marrow cellularity, to evaluate an aplasia component not always expected with ferrokinetic study. Study of bone marrow allowed to precise the site of the erythroblastic abortion; cellular death might occur during the last nitosis of the erythroblastic series (transition from the polychromatophil erythroblasts to the acidophil erythroblasts). In order to delineate the general pattern of erythropoiesis before treatment and when assessing the results of a treatment, besides ferrokinetic measurements, the study of bone marrow biopsy and smears appears relevant.

Adult↗

Blood volume and erythropoiesis in the rat during spaceflight.

A decreased red blood cell mass (RBCM) and plasma volume (PV) have been consistently found in humans after return from spaceflight. Rats flown on the Spacelab Life Sciences-1 mission were studied to assess changes in RBCM, PV, erythropoiesis, and iron economy. The RBCM and PV increased in both ground control and flight animals as expected for growing rats. However on landing day, both the RBCM and PV, when normalized for body mass, were significantly decreased in the spaceflight animals. During an 8-d postflight observation period, iron incorporation into circulating red blood cells was diminished in the flight animals. During the first 4 d postflight, increases in reticulocyte counts were significantly smaller in the flight than the control animals. Fewer erythropoietin-responsive progenitor cells were recovered from the bone marrow of flight animals after landing than control rats. Serum erythropoietin (EPO) levels were the same in both groups. Thus, rats subjected to a 9-d spaceflight had less increase in RBCM than controls and diminished erythropoiesis during an 8-d post-spaceflight observation period. The rat, like humans, appears to require a smaller blood volume in microgravity.

Animals↗

Different sequences of expression of band 3, spectrin, and ankyrin during normal erythropoiesis and erythroleukemia.

Expression of the erythrocyte anion exchanger band 3, and ankyrin and spectrin, two cytoskeletal proteins of the red blood cell membrane, was studied by immunofluorescence using: 1) smears of human bone marrow from healthy donors and from a patient with erythroleukemia, 2) human red blood cell precursors grown in cell culture, and 3) murine erythroleukemia cells grown in cell culture. Double immunostaining with antibodies to band 3 in combination with spectrin or ankyrin revealed that these proteins become expressed synchronously during normal human erythropoiesis. In contrast, both murine erythroleukemia cells (induced by fibronectin and dimethyl sulfoxide to differentiate in vitro) and erythroblasts from a patient suffering from erythroleukemia displayed distinct asynchronicity in expression of these proteins, ie, ankyrin and spectrin were synthesized first, followed by band 3 at a later stage of erythroid development. After the onset of band 3 expression in human erythroleukemia cells, an increase of membrane-associated fluorescence was detectable for both ankyrin and spectrin, supporting the general view that band 3 promotes assembly of the membrane cytoskeleton. These findings indicate that the current concept of a sequential expression of spectrin/ankyrin and band 3 is valid only for erythroleukemia cells or transformed erythropoietic cell lines but does not occur in normal erythropoiesis, during which these proteins become expressed simultaneously.

Animals↗

Stimulation and inhibition of erythropoiesis in donors and hematopoietic effect in irradiated recipient.

Regeneration dynamics in bone marrow and spleen was studied in rats after irradiation of 800 R and transfusion of bone marrow cells from donors treated in different ways. Priority of the microenvironment of the recipient or of the information obtained in cell donors with respect to further hematopoietic cell differentiation was studied in irradiated recipients. Rats irradiated with 800 R were used as recipients in the experiments. The donors of marrow cells were the rats with stimulated or inhibited erythropoiesis. Stimulation of erythropoiesis was induced by bleeding and experimental polycythemia was provoked by packed erythrocytes. According to our results, it can be concluded that the processes of postirradiation hematopoiesis after transplantation of the bone marrow cells depend on the number and proliferative state of both donors and recipient stem cells, and microenvironment, not excluding the information introduced with the donor cell transplant.

Animals↗

Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants.

DESIGN AND METHODS: We hypothesized that treatment with recombinant human erythropoietin (r-HuEPO) would stimulate erythropoiesis and would thereby reduce the need for erythrocyte transfusions in preterm infants. We treated 157 preterm infants born at 26.9 +/- 1.6 weeks of gestation who weighed 924 +/- 183 g at birth with either subcutaneous r-HuEPO (100 U/kg/d, 5 days per week) or placebo for 6 weeks in a randomized, double-blind, controlled clinical trial. All patients received oral iron and were managed according to uniform conservative transfusion guidelines. RESULTS: Treatment with r-HuEPO was associated with fewer erythrocyte transfusions (1.1 +/- 1.5 per infant in the r-HuEPO group versus 1.6 +/- 1.7 per infant in the placebo group; P = .046) and with a reduction in the volume of packed erythrocytes transfused (16.5 +/- 23.0 mL versus 23.9 +/- 25.7 mL per infant; P = .023). Overall, 43% of the infants in the r-HuEPO group and 31% of placebo-treated infants were transfusion-free during the study (P = .18). The volume of blood removed for laboratory tests and the need for respiratory support at the start of treatment had major effects on transfusion requirements independent of r-HuEPO. Reticulocyte counts were higher during treatment in the r-HuEPO group (P = .0001), and r-HuEPO-treated infants had higher hematocrit values at the end of the study (32% versus 27.3% in the placebo group; P = .0001). We found no differences in the incidence of major complications of prematurity between the treatment groups. CONCLUSION: We conclude that treatment with r-HuEPO at a weekly dose of 500 U/kg stimulates erythropoiesis, moderates the course of anemia, is associated with a reduction in erythrocyte transfusions, and appears safe in very low birth weight preterm infants who are receiving iron supplements. Conservative transfusion criteria, minimization of phlebotomy losses, and treatment with r-HuEPO are complementary strategies to reduce erythrocyte transfusions in these infants.

Anemia↗

Stimulation of erythropoiesis by in vivo gene therapy: physiologic consequences of transfer of the human erythropoietin gene to experimental animals using an adenovirus vector.

Erythropoietin (Epo), a 30.4-kD glycoprotein, is the principal regulator of erythropoiesis. To evaluate the concept that in vivo gene transfer might be used as an alternative to recombinant human Epo (rhEpo) in applications requiring a 1- to 3-week stimulation of erythropoiesis, the replication-deficient recombinant adenovirus AdMLP.Epo was constructed by deleting the majority of E1 from adenovirus type 5, and replacing E1 with an expression cassette containing the adenovirus type 5 major late promoter (MLP) and the human Epo gene, including the 3' cis-acting hypoxia response element. In vitro studies showed that infection of the human hepatocyte cell line Hep3B with AdMLP.Epo resulted in a 15-fold increase in Epo production in 24 hours that was enhanced to 116-fold in the presence of a hypoxic stimulus. One-time in vivo administration of AdMLP.Epo (7 x 10(9) plaque-forming units/kg) to the peritoneum of cotton rats caused a marked increase in red blood cell production, with a 2.6-fold increase in bone marrow erythroid precursors by day 4, and sevenfold increase in reticulocyte count by day 7. The hematocrit increased gradually, with a maximum of 64% +/- 4% at day 14 (compared with an untreated baseline of 46% +/- 2%), and a level of 55% +/- 1% at day 24. Furthermore, one-time subcutaneous administration of AdMLP.Epo caused an increase in hematocrit that peaked at 14 days (57% +/- 2%) and was still elevated at day 42. Hematocrit level in animals receiving subcutaneous administration of AdMLP.Epo sustained a long-term increase compared with animals receiving intraperitoneal administration. In the context of these observations, gene therapy with a single administration of an adenovirus vector containing the human EPO gene may provide a means of significantly augmenting the circulating red blood cell mass over the 1- to 3-week period necessary for many clinical applications.

Adenoviridae↗

[The characteristics of iron metabolism in B12-deficient anemias (an evaluation of the functional status of megaloblastic erythropoiesis)].

The review of the literature data and the evidence obtained on 85 own patients with B12-deficiency anemia concerning iron metabolism underlie 3 variants proposed by the authors: pronounced manifestations of secondary sideroachresia before B12 therapy, utilization iron deficiency upon B12 introduction, dimorphic anemia (development of megaloblastic erythropoiesis in prior iron deficiency). The causes of megaloblastic erythropoiesis incompetence (slow rate, hemolytic component, secondary sideroachresia) are discussed.

Anemia, Iron-Deficiency↗

[Effect of neutrophil secretory products on erythropoiesis in erythroblastic islets of bone marrow after hemorrhage].

The effects of activated neutrophilic secretory products on marrow erythroblastic islet erythropoiesis and peripheral blood parameters were studied after experimental blood loss. The supernatant of activated neutrophils was demonstrated to potentiate erythrodieresis in early post-loss period. At the same time the supernatant had a high stimulant effect on erythroblastic islet erythropoiesis. The erythroblastic islets showed increases in new formation and reconstitution, acceleration of amplification wave, which results in peripheral blood reticulocytosis. Thus, neutrophilic secretory products stimulates the synthesis and secretion of central macrophage products, which promotes accelerated maturation of erythroblasts in the erythroblastic islet crown.

Animals↗

Transient erythroblastopenia of childhood. Evidence for cell-mediated suppression of erythropoiesis.

PURPOSE: T cell-mediated red cell aplasia in a 4 1/2-year-old child with transient erythroblastopenia of childhood (TEC) is described. PATIENTS AND METHODS: Erythropoiesis was studied by assessing the colony growth of marrow erythroid progenitors at the time of diagnosis and during recovery. RESULTS: The colony-forming unit-erythroid (CFU-E) growth of whole marrow at diagnosis was only 28% that of the control. T-cell depletion of the patient's marrow was followed by a more than fivefold increase in CFU-E growth, as compared with 20% inhibition of CFU-E and 40% inhibition of burst-forming unit-erythroid (BFU-E) growth in control marrow. The number of colony-forming unit-granulocyte-macrophage (CFU-GM) in both control and patient's marrow was not significantly altered by all of these manipulations. During early and late recovery, CFU-E and BFU-E growth improved substantially, and the effect of T-cell depletion diminished. Increased numbers of peripheral T-suppressor lymphocytes, as well as activation of natural killer (NK) cells and high levels of interferon, all consistent with viral infection, were found at presentation. Clinical recovery was associated with normalization of T-suppressor lymphocyte number. CONCLUSIONS: The results suggest that in this child with TEC, a preceding viral infection may have caused activation of suppressor T-cells and interferon secretion leading to cell-mediated suppression of erythropoiesis.

Anemia↗

[The effect of GH on erythropoiesis in vivo].

It has been demonstrated that the direct and/or indirect stimulation of hematopoiesis is one of the effects of the growth hormone (GH) in vitro. In order to study the effect of GH on erythropoiesis in vivo, the variation of hemochrome in a group of 8 subjects with GH deficiency (GHD) were monitored during a substitutive therapy with biosynthetic GH (rhGH) at dose of 0.4 U/kg/week. Hemoglobin (Hb), hematocrit (Ht), mean corpuscular volume (MCV), number of red blood cells (RBC) were analysed in all subjects at the beginning and after 9 months of treatment. The effectiveness of therapy was demonstrated by statistically significant variations in height, height SDS, growth velocity, serum levels of IGF-I. After 9 months of rhGH therapy, a significant increase was observed in all values considered with exception of MCV. In conclusion Gh would appear to stimulate erythropoiesis, directly or indirectly, and these results would appear to indicate an in vivo confirmation.

Adolescent↗

Both megakaryocytopoiesis and erythropoiesis are induced in mice infected with a retrovirus expressing an oncogenic erythropoietin receptor.

Increasing direct and indirect evidence suggests that erythropoietin (Epo) promotes both erythropoiesis and megakaryocytopoiesis. Here we report that, in mice infected with a recombinant spleen focus-forming retrovirus (SFFV) expressing an oncogenic erythropoietin receptor (EpoR), there was an increase in platelet count preceding the ensuing erythrocytosis. Concurrently, there was a substantial increase in splenic megakaryocytes. Culture of the bone marrow and spleen cells from infected mice showed enhanced numbers of multipotent megakaryocytic progenitors. DNA polymerase chain reaction analysis of individual megakaryocyte-containing colonies showed recombinant SFFV (SFFVcEpoR) proviral integration. Immunofluorescence of spleen sections showed overexpression of EpoR protein in the megakaryocytes. Mice infected with a strain of SFFV also developed splenic megakaryocytosis without activating overexpression of the EpoR in megakaryocytes. This in vivo system shows that a relationship between erythropoiesis and thrombopoiesis can exist at the level of the Epo-EpoR signaling pathway. Also, SFFV-based vectors may be excellent vehicles for the introduction of genes into multipotent, hematopoietic progenitors, in vitro.

Animals↗

[The role of erythropoietin in erythropoiesis regulation in fetuses and newborn infants].

In fetus life erythropoiesis takes place in yolk sack first, then in liver and after that in bone marrow. The regulation of that process still remains unknown. Erythropoietin participates in liver erythropoiesis and in bone marrow. Polycythemia which appears in newborns after delivery is the result of fetus hypozemic metabolic constellation, which leads to excessive erythropoietin production. The substitution of HbF biosynthesis way to HbA (indicating higher tissue then HbF oxygen-exchange ability) is supposedly the reason of EPO secretion drop after delivery. During first 2-3 months of newborn life EPO secretion stimulation takes place at a lower then adults' blood Hb concentration.

Bone Marrow↗

[Role of plasmalemma in the process of aging, elimination and reproduction of erythrocytes: plasmalemmal microvesicles as stimulators of erythropoiesis].

This study summarizes the experimental findings suggesting that plasmalemmal microvesicles formed from red blood cell aging are stimulators of erythropoiesis. The supposed sequence of events consists of microvesicular absorption by the settled macrophages of the liver and spleen, a message of information from circulatory monocytes (and lymphocytes) to the central macrophage of erythropoietic islands and regulation of late erythropoiesis. This is an autoerythronic regulation because it corrects red blood cell reproduction in relation to the rate of cell aging and thus differs from the classical humoral type which regulates erythrocytic reproduction according to visceral oxygen supply.

Animals↗

Diamond-Blackfan anemia: a congenital defect in erythropoiesis.

Diamond-Blackfan anemia (DBA) is a congenital pure red blood cell aplasia diagnosed in the first year of life. Familiarity is apparent in 10% of patients, with all other cases being sporadic. Physical abnormalities are present in at least one third of patients, pointing to a defect in early embryo development. The main clinical sign is profound isolated anemia, with normal numbers and functioning of the other hemopoietic cells. Reticulocyte counts are very low. Bone marrow reflects defective erythropoiesis, showing a very low number of erythropoietic precursors and a reduction of BFU-E progenitor cells. Proliferation and differentiation of the other lineages are normal. The very high erythropoietin (EPO) levels are usually not proportionate to the level of anemia and reflect relative EPO insensitivity, which is also apparent in vitro. Conversely, erythroid progenitors from DBA patients also show a defective or incomplete response to other erythropoietic growth factors, such as IL-3 or IL-6. A significant response has been observed in vitro to stem cell factor in many, but not all patients. Many patients respond clinically to corticosteroids and some develop hematologic remissions, both after corticosteroids and spontaneously. Patients who do not respond to corticosteroids and those who have to discontinue treatment because of side effects must rely on chronic transfusion and are thus exposed to all its complications. Bone marrow transplantation has been performed in some individuals, usually with a successful outcome. This suggests a normal marrow microenvironment and rules out the hypothesis of defective stromal cell function. The variable clinical and biological patterns may be the expression of multiple etiologies or represent variable expressivity of a single genetic defect. Only identification of the responsible gene(s) will solve this question. Growth factors exerting an effect on erythropoiesis (and relative receptors) or transacting proteins which regulate their expression are likely candidates in the hunt for a causal gene.

Animals↗

[Heterogeneity of ineffective erythropoiesis in myelodysplastic syndromes evaluated by application of newly devised parameters based on ferroerythrokinetic data].

Ineffective erythropoiesis was evaluated in 100 studies in 87 patients with myelodysplastic syndromes (MDS) applying newly devised parameters based on ferroerythrokinetic (FEK) data including erythron transferrin uptake (ETU). The efficiency ratio (R-Ef) was calibrated with V-2, the second canonical discriminant variate which underwent axis rotation. Based on discriminated FEK patterns, as previously reported, the patients were classified into five types i.e. I-z, ineffective, H-z, hemolytic hyperplastic, O-z, hypoplastic, I-H-z and I-O-z, combination of these, groups. The proportion of I-z group was 48% and that of I-H-z and I-O-z groups was 30%. Significant correlations were obtained in I-z group between R-Ef and ETU (r = -0.628), unclear abnormality scores (R = 0.664) or ringed sideroblast scores (R = 0.742), scored by dummy variables regression. In the other groups, significant deviation from these correlations was observed, indicating that there is an obvious heterogeneity in MDS patients concerning association or dissociation of morphological abnormality, in addition to hyperplasia of erythroblasts, with or from ineffective erythropoiesis.

Erythrocytes↗

Initiation of murine embryonic erythropoiesis: a spatial analysis.

Hematopoiesis in the mouse conceptus begins in the visceral yolk (VYS), with primitive erythroblasts first evident in blood islands at the headfold stage (E8.0). VYS erythropoiesis is decreased or abrogated by targeted disruption of the hematopoietic transcription factors tal-1, rbtn2, GATA-1, and GATA-2. To better understand the potential roles of these genes, and to trace the initial temporal and spatial development of mammalian embryonic hematopoiesis, we examined their expression patterns, and that of betaH1-globin, in normal mouse conceptuses by means of in situ hybridization. Attention was focused on the 36-hour period from mid-primitive streak to early somite stages (E7.25 to E8.5), when the conceptus undergoes rapid morphologic changes with formation of the yolk sac and blood islands. Each of these genes was expressed in extraembryonic mesoderm, from which blood islands are derived. This VYS expression occurred in a defined temporal sequence: tal-1 and rbtn2 transcripts were detected earlier than the others, followed by GATA-2 and GATA-1, and then by betaH1-globin. Transcripts for all of these genes were present in VYS mesoderm cell masses at the neural plate stage (E7.5), indicating commitment of these cells to the erythroid lineage before the appearance of morphologically recognizable erythroblasts. By early somite stages (E8.5), GATA-2 mRNA expression is downregulated in VYS blood islands as terminal primitive erythroid differentiation proceeds. We conclude that primitive mammalian erythropoiesis arises during gastrulation through the ordered temporal expression of tal-1, rbtn2, GATA2, and GATA-1 in a subset of extraembryonic mesoderm cells. During the stages analyzed, tal-1 and rbtn2 expression was also present in posterior embryonic mesoderm, while GATA-1 and GATA-2 expression was evident in extraembryonic tissues of ectodermal origin.

Adaptor Proteins, Signal Transducing↗